Investigating how erythropoietin affects immune responses in transplantation
Erythropoietin and trained immunity intransplantation
This study is looking at how a substance called erythropoietin (EPO) can help improve the way your immune system works, especially in people who have had organ transplants, with the hope of making transplants last longer and reducing the chances of rejection.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11133563 on NIH RePORTER |
What this research studies
This research explores the role of erythropoietin (EPO) in modulating immune responses, particularly focusing on macrophages and their 'trained immunity' in the context of organ transplantation. By examining how EPO influences the behavior of immune cells, the study aims to identify new therapeutic strategies that could improve long-term graft survival and reduce the risk of organ rejection. The research involves both animal models and human cells to understand the underlying mechanisms and potential benefits of EPO treatment in transplant patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 21 and older who are undergoing or have undergone allogeneic organ transplantation.
Not a fit: Patients who are not undergoing transplantation or those with conditions unrelated to immune response modulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved outcomes for transplant patients by enhancing graft survival and reducing the incidence of rejection.
How similar studies have performed: Previous research has shown promising results in using erythropoietin to modulate immune responses, indicating potential for success in this approach.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Cravedi, Paolo — Icahn School of Medicine at Mount Sinai
- Study coordinator: Cravedi, Paolo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.